Skip to main content
SpringerLink
Log in

The PI3K/AKT/mTOR signaling pathway inhibitors enhance radiosensitivity in cancer cell lines

  • Review
  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

Introduction

Radiotherapy is one of the most common types of cancer treatment modalities. Radiation can affect both cancer and normal tissues, which limits the whole delivered dose. It is well documented that radiation activates phosphatidylinositol 3-kinase (PI3K) and AKT signaling pathway; hence, the inhibition of this pathway enhances the radiosensitivity of tumor cells. The mammalian target of rapamycin (mTOR) is a regulator that is involved in autophagy, cell growth, proliferation, and survival.

Conclusion

The inhibition of mTOR as a downstream mediator of the PI3K/AKT signaling pathway represents a vital option for more effective cancer treatments. The combination of PI3K/AKT/mTOR inhibitors with radiation can increase the radiosensitivity of malignant cells to radiation by autophagy activation. Therefore, this review aims to discuss the impact of such inhibitors on the cell response to radiation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Data availability

All the articles that are mentioned in this review are available online.

References

  1. Thorpe LM, Yuzugullu H, Zhao JJ (2015) PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer 15(1):7–24

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12(1):9–22

    CAS  PubMed  Google Scholar 

  3. Menon S, Manning BD (2008) Common corruption of the mTOR signaling network in human tumors. Oncogene 27(2):S43–S51

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Zaytseva YY et al (2012) mTOR inhibitors in cancer therapy. Cancer Lett 319(1):1–7

    CAS  PubMed  Google Scholar 

  5. Pedroza DA et al (2020) Progesterone receptor membrane component 1 promotes the growth of breast cancers by altering the phosphoproteome and augmenting EGFR/PI3K/AKT signalling. Br J Cancer 123:1326–1335

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Markova B et al (2010) Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-γ1-driven activation of mTOR/p70S6-kinase pathway. Oncogene 29(5):739–751

    CAS  PubMed  Google Scholar 

  7. Cornu M, Albert V, Hall MN (2013) mTOR in aging, metabolism, and cancer. Curr Opin Genet Dev 23(1):53–62

    CAS  PubMed  Google Scholar 

  8. Zhou H, Luo Y, Huang S (2010) Updates of mTOR inhibitors. Anti-Cancer Agents Med Chem 10(7):571–581

    CAS  Google Scholar 

  9. Francipane MG, Lagasse E (2014) mTOR pathway in colorectal cancer: an update. Oncotarget 5(1):49

    PubMed  Google Scholar 

  10. Bellizzi AM et al (2010) The mTOR pathway is frequently activated in pancreatic ductal adenocarcinoma and chronic pancreatitis. Appl Immunohistochem Mol Morphol 18(5):442–447

    CAS  PubMed  Google Scholar 

  11. Li X et al (2016) PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma. Oncotarget 7(22):33440

    PubMed  PubMed Central  Google Scholar 

  12. Hütt-Cabezas M et al (2013) Activation of mTORC1/mTORC2 signaling in pediatric low-grade glioma and pilocytic astrocytoma reveals mTOR as a therapeutic target. Neurooncology 15(12):1604–1614

    Google Scholar 

  13. Bilanges B, Posor Y, Vanhaesebroeck B (2019) PI3K isoforms in cell signalling and vesicle trafficking. Nat Rev Mol Cell Biol 20(9):515–534

    CAS  PubMed  Google Scholar 

  14. Lee Y-R, Chen M, Pandolfi PP (2018) The functions and regulation of the PTEN tumour suppressor: new modes and prospects. Nat Rev Mol Cell Biol 19(9):547–562

    CAS  PubMed  Google Scholar 

  15. Hoxhaj G, Manning BD (2020) The PI3K–AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer 20(2):74–88

    CAS  PubMed  Google Scholar 

  16. Valvezan AJ, Manning BD (2019) Molecular logic of mTORC1 signalling as a metabolic rheostat. Nat Metab 1(3):321–333

    CAS  PubMed  Google Scholar 

  17. Chen X et al (2018) Cryo-EM structure of human mTOR complex 2. Cell Res 28(5):518–528

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Dibble CC, Manning BD (2013) Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. Nat Cell Biol 15(6):555–564

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Bracho-Valdés I et al (2011) mTORC1‐and mTORC2‐interacting proteins keep their multifunctional partners focused. IUBMB Life 63(10):896–914

    PubMed  Google Scholar 

  20. Bond P (2016) Regulation of mTORC1 by growth factors, energy status, amino acids and mechanical stimuli at a glance. J Int Soc Sports Nutr 13(1):8

    PubMed  PubMed Central  Google Scholar 

  21. Showkat M, Beigh MA, Andrabi KI (2014) mTOR signaling in protein translation regulation: implications in cancer genesis and therapeutic interventions. Mol Biol Int 2014:1–14

    Google Scholar 

  22. Oh WJ, Jacinto E (2011) mTOR complex 2 signaling and functions. Cell Cycle 10(14):2305–2316

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Kaizuka T et al (2010) Tti1 and Tel2 are critical factors in mammalian target of rapamycin complex assembly. J Biol Chem 285(26):20109–20116

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Chang L et al (2015) Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance. Crit Rev Oncol Hematol 96(3):507–517

    PubMed  Google Scholar 

  25. Edwards E et al (2002) Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation. Cancer Res 62(16):4671–4677

    CAS  PubMed  Google Scholar 

  26. Schmidt-Ullrich RK et al (2003) ERBB receptor tyrosine kinases and cellular radiation responses. Oncogene 22(37):5855–5865

    CAS  PubMed  Google Scholar 

  27. Zoncu R, Efeyan A, Sabatini DM (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12(1):21–35

    CAS  PubMed  Google Scholar 

  28. Wang L et al (2016) Autophagy inhibition sensitizes WYE-354-induced anti-colon cancer activity in vitro and in vivo. Tumor Biol 37(9):11743–11752

    CAS  Google Scholar 

  29. Pan XD et al (2017) Concurrent inhibition of mTORC1 and mTORC2 by WYE-687 inhibits renal cell carcinoma cell growth in vitro and in vivo. PloS ONE. https://doi.org/10.1371/journal.pone.0172555

    Article  PubMed  PubMed Central  Google Scholar 

  30. Xing X et al (2014) PP242 suppresses cell proliferation, metastasis, and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway. Anti-Cancer Drugs 25(10):1129

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Huang H et al (2017) Two mTOR inhibitors, rapamycin and Torin 1, differentially regulate iron-induced generation of mitochondrial ROS. Biometals 30(6):975–980

    CAS  PubMed  Google Scholar 

  32. Yongxi T et al (2015) Autophagy inhibition sensitizes KU-0063794-mediated anti-HepG2 hepatocellular carcinoma cell activity in vitro and in vivo. Biochem Biophys Res Commun 465(3):494–500

    PubMed  Google Scholar 

  33. Yu K et al (2009) Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res 69(15):6232–6240

    CAS  PubMed  Google Scholar 

  34. Garcia-Echeverria C (2011) Blocking the mTOR pathway: a drug discovery perspective. Portland Press Ltd, London

    Google Scholar 

  35. Zhou H-Y, Huang S-L (2012) Current development of the second generation of mTOR inhibitors as anticancer agents. Chin J Cancer 31(1):8

    PubMed  PubMed Central  Google Scholar 

  36. Mayer IA, Arteaga CL (2016) The PI3K/AKT pathway as a target for cancer treatment. Ann Rev Med 67:11–28

    CAS  PubMed  Google Scholar 

  37. Rizzieri DA et al (2008) A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 14(9):2756–2762

    CAS  PubMed  Google Scholar 

  38. Sinclair C et al (2017) mTOR regulates metabolic adaptation of APCs in the lung and controls the outcome of allergic inflammation. Science 357(6355):1014–1021

    CAS  PubMed  PubMed Central  Google Scholar 

  39. Eynott PR et al (2003) Effects of cyclosporin A and a rapamycin derivative (SAR943) on chronic allergic inflammation in sensitized rats. Immunology 109(3):461–467

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Chibana H et al (2017) Interleukin-1β is associated with coronary endothelial dysfunction in patients with mTOR-inhibitor-eluting stent implantation. Heart Vessels 32(7):823–832

    PubMed  Google Scholar 

  41. Rini BI (2008) Temsirolimus, an inhibitor of mammalian target of rapamycin. Clin Cancer Res 14(5):1286–1290

    CAS  PubMed  Google Scholar 

  42. Liu Q et al (2009) mTOR mediated anti-cancer drug discovery. Drug Discov Today Ther Strateg 6(2):47–55

    CAS  PubMed  PubMed Central  Google Scholar 

  43. Alvarado Y et al (2011) Clinical activity of mammalian target of rapamycin inhibitors in solid tumors. Target Oncol 6(2):69–94

    PubMed  Google Scholar 

  44. Tian T, Li X, Zhang J (2019) mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy. Int J Mol Sci 20(3):755

    CAS  PubMed Central  Google Scholar 

  45. Tam SY, Wu VWC, Law HKW (2017) Influence of autophagy on the efficacy of radiotherapy. Radiat Oncol 12(1):57

    PubMed  PubMed Central  Google Scholar 

  46. Yoo YJ et al (2017) An overview of rapamycin: from discovery to future perspectives. J Ind Microbiol Biotechnol 44(4–5):537–553

    CAS  PubMed  Google Scholar 

  47. Weppler SA et al (2007) Response of U87 glioma xenografts treated with concurrent rapamycin and fractionated radiotherapy: possible role for thrombosis. Radiother Oncol 82(1):96–104

    CAS  PubMed  Google Scholar 

  48. Dumont RA et al (2013) Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin. J Nucl Med 54(5):762–769

    CAS  PubMed  Google Scholar 

  49. Eshleman JS et al (2002) Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res 62(24):7291–7297

    CAS  PubMed  Google Scholar 

  50. Anandharaj A, Cinghu S, Park W-Y (2011) Rapamycin-mediated mTOR inhibition attenuates survivin and sensitizes glioblastoma cells to radiation therapy. Acta Biochim Biophys Sin 43(4):292–300

    CAS  PubMed  Google Scholar 

  51. Buijsen J et al (2015) A phase I–II study on the combination of rapamycin and short course radiotherapy in rectal cancer. Radiother Oncol 116(2):214–220

    CAS  PubMed  Google Scholar 

  52. Dancey JE, Curiel R, Purvis J (2009) Evaluating temsirolimus activity in multiple tumors: a review of clinical trials. Elsevier, Amsterdam

    Google Scholar 

  53. Ekshyyan O et al (2009) Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma. Mol Cancer Ther 8(8):2255–2265

    CAS  PubMed  PubMed Central  Google Scholar 

  54. Du Y, Peyser ND, Grandis JR (2014) Integration of molecular targeted therapy with radiation in head and neck cancer. Pharmacol Ther 142(1):88–98

    CAS  PubMed  Google Scholar 

  55. Ushijima H et al (2015) Radio-sensitization effect of an mTOR inhibitor, temsirolimus, on lung adenocarcinoma A549 cells under normoxic and hypoxic conditions. J Radiat Res 56(4):663–668

    CAS  PubMed  PubMed Central  Google Scholar 

  56. Cao C et al (2006) Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res 66(20):10040–10047

    CAS  PubMed  Google Scholar 

  57. Yu C-C et al (2014) RAD001 enhances the radiosensitivity of SCC4 oral cancer cells by inducing cell cycle arrest at the G2/M checkpoint. Anticancer Res 34(6):2927–2935

    CAS  PubMed  Google Scholar 

  58. Kim KW et al (2008) Autophagy upregulation by inhibitors of caspase-3 and mTOR enhances radiotherapy in a mouse model of lung cancer. Autophagy 4(5):659–668

    CAS  PubMed  Google Scholar 

  59. Gelsomino F et al (2017) A Dose-finding and biomarker evaluation phase Ib study of everolimus in association with 5-fluorouracil and pelvic radiotherapy as neoadjuvant treatment of locally advanced rectal cancer (E-LARC Study). Clin Colorectal Cancer 16(4):410-415.e1

    PubMed  Google Scholar 

  60. Azria D et al (2013) Concurrent treatment with everolimus (RAD001) and hormonoradiotherapy in high-risk locally advanced prostate cancer: results of a phase I trial. J Clin Oncol 31(6_suppl):150–150

    Google Scholar 

  61. Narayan V et al (2017) Phase 1 trial of everolimus and radiation therapy for salvage treatment of biochemical recurrence in prostate cancer patients following prostatectomy. Int J Radiat Oncol Biol Phys 97(2):355–361

    CAS  PubMed  Google Scholar 

  62. de Melo AC et al (2016) A phase I study of mTOR inhibitor everolimus in association with cisplatin and radiotherapy for the treatment of locally advanced cervix cancer: PHOENIX I. Cancer Chemother Pharmacol 78(1):101–109

    PubMed  Google Scholar 

  63. Sarkaria JN et al (2011) North central cancer treatment group phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 81(2):468–475

    CAS  PubMed  Google Scholar 

  64. Ma DJ et al (2015) A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. Neuro Oncol 17(9):1261–1269

    CAS  PubMed  Google Scholar 

  65. Chinnaiyan P et al (2018) A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG oncology RTOG 0913. Neuro Oncol 20(5):666–673

    CAS  PubMed  Google Scholar 

  66. Deutsch E et al (2015) Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer. Ann Oncol 26(6):1223–1229

    CAS  PubMed  Google Scholar 

  67. Prasad G et al (2011) Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro Oncol 13(4):384–392

    CAS  PubMed  PubMed Central  Google Scholar 

  68. Wen PY et al (2015) Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma. Neuro Oncol 17(9):1275–1283

    CAS  PubMed  PubMed Central  Google Scholar 

  69. Gil del Alcazar, CR et al (2014) Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma. Clin Cancer Res 20(5):1235–1248

    Google Scholar 

  70. Cerniglia GJ et al (2012) Inhibition of autophagy as a strategy to augment radiosensitization by the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Mol Pharmacol 82(6):1230–1240

    CAS  PubMed  PubMed Central  Google Scholar 

  71. Gao M et al (2012) Dual PI3K/mTOR blockade by NVP-BEZ235 sensitizes head and neck squamous cell carcinoma to radiotherapy. Cancer Res. https://doi.org/10.1158/1538-7445

    Article  PubMed  PubMed Central  Google Scholar 

  72. Chen YH et al (2015) Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor is an effective radiosensitizer for colorectal cancer. Cancer Lett 357(2):582–590

    CAS  PubMed  Google Scholar 

  73. Chen Y-H et al (2019) Maintenance BEZ235 treatment prolongs the therapeutic effect of the combination of BEZ235 and radiotherapy for colorectal cancer. Cancers 11(8):1204

    CAS  PubMed Central  Google Scholar 

  74. Chang L et al (2014) PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways. Cell Death Dis 5(10):e1437–e1437

    CAS  PubMed  PubMed Central  Google Scholar 

  75. Potiron VA et al (2013) Radiosensitization of prostate cancer cells by the dual PI3K/mTOR inhibitor BEZ235 under normoxic and hypoxic conditions. Radiother Oncol 106(1):138–146

    CAS  PubMed  Google Scholar 

  76. Zhu W, Fu W, Hu L (2013) NVP-BEZ235, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, prominently enhances radiosensitivity of prostate cancer cell line PC-3. Cancer Biother Radiopharm 28(9):665–673

    CAS  PubMed  Google Scholar 

  77. Kuger S et al (2014) Novel PI3K and mTOR inhibitor NVP-BEZ235 radiosensitizes breast cancer cell lines under normoxic and hypoxic conditions. Breast Cancer 8:39–49

    CAS  PubMed  PubMed Central  Google Scholar 

  78. Wang WJ et al (2013) NVP-BEZ235, a novel dual PI3K/mTOR inhibitor, enhances the radiosensitivity of human glioma stem cells in vitro. Acta Pharmacol Sin 34(5):681–690

    PubMed  PubMed Central  Google Scholar 

  79. Kuger S et al (2013) Radiosensitization of glioblastoma cell lines by the dual PI3K and mTOR inhibitor NVP-BEZ235 depends on drug-irradiation schedule. Transl Oncol 6(2):169-1N16

    PubMed  PubMed Central  Google Scholar 

  80. Leiker AJ et al (2015) Radiation enhancement of head and neck squamous cell carcinoma by the dual PI3K/mTOR inhibitor PF-05212384. Clin Cancer Res 21(12):2792–2801

    CAS  PubMed  PubMed Central  Google Scholar 

  81. Wilson GD et al (2021) Dacomitinib and gedatolisib in combination with fractionated radiation in head and neck cancer. Clin Transl Radiat Oncol 26:15–23

    PubMed  Google Scholar 

  82. Kahn J et al (2014) The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells. Neurooncology 16(1):29–37

    CAS  Google Scholar 

  83. Hayman TJ et al (2014) The ATP-competitive mTOR inhibitor INK128 enhances in vitro and in vivo radiosensitivity of pancreatic carcinoma cells. Clin Cancer Res 20(1):110–119

    CAS  PubMed  Google Scholar 

  84. Connolly E et al (2011) TORC1/2 inhibition with concurrent radiation controls inflammatory breast cancer in a preclinical animal model through selective blockade of translation. Int J Radiat Oncol Biol Phys 81(2):S751

    Google Scholar 

  85. Luo J et al (2018) Torin2 enhances the radiosensitivity of MCF–7 breast cancer cells by downregulating the mTOR signaling pathway and ATM phosphorylation. Mol Med Rep 17(1):366–373

    CAS  PubMed  Google Scholar 

  86. Chang L et al (2019) A low dose of AZD8055 enhances radiosensitivity of nasopharyngeal carcinoma cells by activating autophagy and apoptosis. Am J Cancer Res 9(9):1922

    CAS  PubMed  PubMed Central  Google Scholar 

  87. Shu H et al (2007) SF1126, a novel integrin-targeting phosphatidylinositol-3 kinase inhibitor, has radiosensitizing and anti-tumor effects in glioma model systems. Int J Radiat Oncol Biol Phys 69(3):S98

    Google Scholar 

  88. Chen Y et al (2015) Combining radiation with autophagy inhibition enhances suppression of tumor growth and angiogenesis in esophageal cancer. Mol Med Rep 12(2):1645–1652

    CAS  PubMed  PubMed Central  Google Scholar 

  89. Nakamura JL et al (2005) PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas. J Neurooncol 71(3):215–222

    CAS  PubMed  Google Scholar 

  90. Kao GD et al (2007) Inhibition of phosphatidylinositol-3-OH kinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation. J Biol Chem 282(29):21206–21212

    CAS  PubMed  Google Scholar 

  91. Gupta AK et al (2003) Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002. Int J Radiat Oncol Biol Phys 56(3):846–853

    CAS  PubMed  Google Scholar 

  92. Li HF, Kim JS, Waldman T (2009) Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells. Radiat Oncol 4:43

    PubMed  PubMed Central  Google Scholar 

  93. Bai R et al (2016) The effect of PI3K inhibitor LY294002 and gemcitabine hydrochloride combined with ionizing radiation on the formation of vasculogenic mimicry of Panc-1 cells in vitro and in vivo. Neoplasma 63(1):80–92

    CAS  PubMed  Google Scholar 

  94. Raynaud FI et al (2007) Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res 67(12):5840–5850

    CAS  PubMed  Google Scholar 

  95. Prevo R et al (2008) Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity. Cancer Res 68(14):5915–5923

    CAS  PubMed  Google Scholar 

  96. Djuzenova CS et al (2016) Dual PI3K- and mTOR-inhibitor PI-103 can either enhance or reduce the radiosensitizing effect of the Hsp90 inhibitor NVP-AUY922 in tumor cells: the role of drug-irradiation schedule. Oncotarget 7(25):38191–38209

    PubMed  PubMed Central  Google Scholar 

  97. Liu T et al (2015) Dual PI3K/mTOR inhibitors, GSK2126458 and PKI-587, suppress tumor progression and increase radiosensitivity in nasopharyngeal carcinoma. Mol Cancer Ther 14(2):429–439

    CAS  PubMed  Google Scholar 

  98. Xue Q et al (2008) Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability. Cancer Res 68(22):9551–9557

    CAS  PubMed  PubMed Central  Google Scholar 

  99. Diaz R et al (2009) The novel Akt inhibitor palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer. Br J Cancer 100(6):932–940

    CAS  PubMed  PubMed Central  Google Scholar 

  100. Park JH et al (2017) Radiosensitization of the PI3K inhibitor HS-173 through reduction of DNA damage repair in pancreatic cancer. Oncotarget 8(68):112893–112906

    PubMed  PubMed Central  Google Scholar 

Download references

Funding

This work was not funded by any organization.

Author information

Authors and Affiliations

  1. Department of Radiology and Nuclear Medicine, Faculty of Medicine, Cardiovascular Research Center, Mazandaran University of Medical Sciences, Sari, Iran

    Alireza Mardanshahi, Seyed Mohammad Abedi & Sajjad Molavipordanjani

  2. Department of Radiopharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran

    Nasrin Abbasi Gharibkandi

  3. Department of Chemistry, Science and Research Branch, Islamic Azad University, Tehran, Iran

    Samaneh Vaseghi

Authors
  1. Alireza Mardanshahi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nasrin Abbasi Gharibkandi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Samaneh Vaseghi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Seyed Mohammad Abedi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sajjad Molavipordanjani
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors discussed the results and contributed to the final manuscript.

Corresponding author

Correspondence to Sajjad Molavipordanjani.

Ethics declarations

Conflict of interest

The authors declared no conflict of interest.

Ethical approval

This study was approved by the Ethical Committee of Mazandaran University of Medical Sciences, Iran.

Consent to publish

All authors agreed to publish this work.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mardanshahi, A., Gharibkandi, N.A., Vaseghi, S. et al. The PI3K/AKT/mTOR signaling pathway inhibitors enhance radiosensitivity in cancer cell lines. Mol Biol Rep 48, 1–14 (2021). https://doi.org/10.1007/s11033-021-06607-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-021-06607-3

Keywords

Search

Navigation